Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1r agonist that has demonstrated up to 20% body weight loss and improvement in noninvasive hepatic steatosis (105, 106). Here, GIP is linked to fatty liver disease.